EX-23.2 3 tm2124117d4_ex23-2.htm EXHIBIT 23.2

 

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-255841) and Form S-8 (Nos. 333-253883, 333-237041, 333-229975 and 333-222758) of VYNE Therapeutics Inc. of our report dated March 12, 2020, except for the effects of the reverse stock split discussed in Note 1, and except for the effects of the merger exchange ratio discussed in Note 3, and except for the effects of disclosing the reconciliation of income taxes at the U.S. federal statutory rate discussed in Note 14, as to which the date is March 4, 2021 relating to the financial statements, which appears in this Form 8-K.

 

/s/ Kesselman & Kesselman    
Certified Public Accountants (lsr.)  
A member firm of PricewaterhouseCoopers International Limited  
   
Tel-Aviv, Israel  
August 12, 2021